Overview

Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate Safety and Efficacy of Danaparoid vs Argatroban

Status:
Active, not recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)

Phase:

Phase 3

Details

Lead Sponsor:

Aspen Global Incorporated

Treatments:

Argatroban
Danaparoid
Danaproid
Dermatan Sulfate